Beijing Tiantan Overview
- Year Founded
-
1919
- Status
-
Public
- Employees
-
5,205
- Stock Symbol
-
600161
- Investments
-
1
- Share Price
-
$1.80
- (As of Friday Closing)
Beijing Tiantan General Information
Description
Beijing Tiantan Biological Products Corp Ltd uses healthy human plasma and specifically immunized human plasma as raw materials and adopts genetic recombination technology to develop and produce blood products and engage in the blood product business. The company's main products include human albumin, human immunoglobulin (pH4) for intravenous injection, human hepatitis B immunoglobulin, human immunoglobulin, human rabies immunoglobulin, human histamine immunoglobulin, and others.
Contact Information
Website
www.btbp.com.cnCorporate Office
- No. 2, Shuangqiao Road
- Chaoyang District
- Beijing, 100024
- China
Corporate Office
- No. 2, Shuangqiao Road
- Chaoyang District
- Beijing, 100024
- China
Beijing Tiantan Stock Performance
As of 13-Nov-2026, Beijing Tiantan’s stock price is $1.80. Its current market cap is $3.56B with 1.98B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.80 | $1.83 | $1.64 - $2.62 | $3.56B | 1.98B | 12.6M | $0.05 |
Beijing Tiantan Financials Summary
As of 30-Sep-2026, Beijing Tiantan has a trailing 12-month revenue of $806M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,954,723 | 4,877,672 | 5,339,356 | 6,895,814 |
| Revenue | 805,935 | 857,706 | 840,624 | 732,230 |
| EBITDA | 177,239 | 311,963 | 396,212 | 284,775 |
| Net Income | 101,577 | 151,688 | 215,898 | 156,877 |
| Total Assets | 2,506,945 | 2,370,120 | 2,173,877 | 2,001,532 |
| Total Debt | 11,822 | 22,984 | 7,372 | 5,977 |
Beijing Tiantan Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Beijing Tiantan Acquisitions (1)
Beijing Tiantan’s most recent deal was a Merger/Acquisition with Xi'an Huitian Blood Products for . The deal was made on 06-Sep-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Xi'an Huitian Blood Products | 06-Sep-2022 | Merger/Acquisition | Pharmaceuticals |
Beijing Tiantan ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
30.9 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Beijing Tiantan FAQs
-
When was Beijing Tiantan founded?
Beijing Tiantan was founded in 1919.
-
Where is Beijing Tiantan headquartered?
Beijing Tiantan is headquartered in Beijing, China.
-
What is the size of Beijing Tiantan?
Beijing Tiantan has 5,205 total employees.
-
What industry is Beijing Tiantan in?
Beijing Tiantan’s primary industry is Drug Delivery.
-
Is Beijing Tiantan a private or public company?
Beijing Tiantan is a Public company.
-
What is Beijing Tiantan’s stock symbol?
The ticker symbol for Beijing Tiantan is 600161.
-
What is the current stock price of Beijing Tiantan?
As of 13-Nov-2026 the stock price of Beijing Tiantan is $1.80.
-
What is the current market cap of Beijing Tiantan?
The current market capitalization of Beijing Tiantan is $3.56B.
-
What is Beijing Tiantan’s current revenue?
The trailing twelve month revenue for Beijing Tiantan is $806M.
-
What is Beijing Tiantan’s annual earnings per share (EPS)?
Beijing Tiantan’s EPS for 12 months was $0.05.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
